CAR-T Cell Therapy for Relapsed Pancreatic Cancer
What You Need to Know Before You Apply
What is the purpose of this trial?
The purpose of this gene therapy research study is to test the safety and tolerability of using a new treatment called autologous T lymphocyte chimeric antigen receptor cells against the B7-H3 antigen (iC9.CAR.B7-H3 T cells) in patients with pancreatic ductal adenocarcinoma that came back after receiving standard therapy for this cancer. The iC9.CAR.B7-H3 treatment is experimental and has not been approved by the Food and Drug Administration.
Do I need to stop my current medications for this trial?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial team or your doctor.
Is CAR-T cell therapy safe for humans?
How is the iC9-CAR.B7-H3 T cell treatment different from other treatments for pancreatic cancer?
The iC9-CAR.B7-H3 T cell treatment is unique because it uses genetically engineered T cells to specifically target the B7-H3 protein found on pancreatic cancer cells, potentially offering a more precise attack on the cancer with less harm to normal tissues. This approach is different from traditional treatments as it harnesses the body's immune system to fight the cancer, which is a novel strategy for this type of cancer.12367
What data supports the effectiveness of this treatment for relapsed pancreatic cancer?
Who Is on the Research Team?
Ashwin Somasundaram, MD
Principal Investigator
UNC Lineberger Comprehensive Cancer Center
Are You a Good Fit for This Trial?
This trial is for adults over 18 with pancreatic ductal adenocarcinoma that has returned after standard treatment. Participants must be able to perform daily activities with minimal assistance (ECOG Performance Status of 0-1) and agree to use effective contraception methods. Those with other cancers or unwilling to follow study procedures are excluded.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Lymphodepletion
Participants undergo lymphodepleting chemotherapy prior to CAR-T cell infusion
Treatment
Participants receive iC9.CAR.B7-H3 T cells infusion
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- iC9-CAR.B7-H3 T cells
Find a Clinic Near You
Who Is Running the Clinical Trial?
UNC Lineberger Comprehensive Cancer Center
Lead Sponsor
M.D. Anderson Cancer Center
Collaborator